{"entity":{"id":"hcw-biologics","kind":"company","name":"HCW Biologics","aka":["HCW Biologics Inc."],"tldr":"HCW Biologics is a Florida company making fusion proteins that act on the immune system, mainly for inflammatory diseases. For cancer, its lead product, HCW11-018b, is an injection under the skin that steers the body's T cells onto solid tumours and is being prepared for a first trial in people.","summary":"HCW Biologics Inc., based in Miramar, Florida and listed on Nasdaq as HCWB, describes itself in its 2026 S-1 as a clinical-stage company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune and proinflammatory diseases, cancer and senescence-associated dysplasia. Its founder and chief executive, Hing C. Wong, led the development of the IL-15 receptor agonist that was sold to ImmunityBio in 2017 and later approved for BCG-unresponsive non-muscle invasive bladder cancer.\n\nIn oncology, the filing names HCW11-018b, a tetravalent T-cell engager given by subcutaneous injection to treat solid tumours. After a Type B pre-IND meeting with the FDA in July 2026, the company says it is preparing an IND for a Phase 1 trial in solid tumours, to be filed in the first half of 2027. Its most advanced clinical compound is an IL-2 fusion protein complex in a Phase 1 trial in alopecia areata, and it has agreed to distribute a reagent molecule for cell therapy manufacturing through Akron Biotech.","asOf":"2026-11-04","links":[{"label":"SEC EDGAR: HCW Biologics S-1, October 2026","url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm"},{"label":"Official website","url":"https://hcwbiologics.com/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["t-cell-engager"],"targets":[],"drugs":["hcw11-018b"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read from the S-1 filed on EDGAR on 2 October 2026 (prospectus summary and cover page) on 4 November 2026. Only the oncology programme is recorded as a product; the inflammation programmes are described without codes. Founding year not read."],"hq":"Miramar, FL","country":"US","companyType":"biotech","website":"https://hcwbiologics.com/","ticker":"HCWB","stage":"public","investors":[],"funding":[]},"route":"/companies/hcw-biologics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"hcw11-018b","kind":"drug","name":"HCW11-018b","route":"/drugs/hcw11-018b/"}]}}